EWTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EWTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Edgewise Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $21.21 Mil. Edgewise Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $340.04 Mil. Therefore, Edgewise Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.06.
The historical data trend for Edgewise Therapeutics's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edgewise Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Liabilities-to-Assets | 1.69 | 1.26 | 0.04 | 0.06 | 0.06 |
Edgewise Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.06 | 0.05 | 0.06 | 0.07 | 0.06 |
For the Biotechnology subindustry, Edgewise Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Edgewise Therapeutics's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Edgewise Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Liabilities-to-Assets (A: Dec. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 21.205 | / | 340.035 | |
= | 0.06 |
Edgewise Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as
Liabilities-to-Assets (Q: Dec. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 21.205 | / | 340.035 | |
= | 0.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edgewise Therapeutics (NAS:EWTX) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Edgewise Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
John R Moore | officer: General Counsel | 3200 WALNUT ST, BOULDER CO 80301 |
Alan J Russell | director, officer: Chief Scientific Officer | 3415 COLORADO AVE, BOULDER CO 80303 |
Jonathan C Fox | director | C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
R Michael Carruthers | officer: Chief Financial Officer | 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301 |
Behrad Derakhshan | officer: Chief Business Officer | 3415 COLORADO AVE., BOULDER CO 80303 |
Kevin Koch | director, officer: President and CEO | 3200 WALNUT ST, BOULDER CO 80301 |
Joanne M. Donovan | officer: CMO | C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139 |
Marc Semigran | officer: Chief Development Officer | C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Peter A. Thompson | director, 10 percent owner | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Orbimed Capital Gp Vi Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By GuruFocus Research • 11-09-2023
By Business Wire • 01-19-2024
By Business Wire • 09-26-2023
By Business Wire Business Wire • 12-21-2022
By Business Wire • 11-01-2023
By Business Wire • 12-19-2023
By Business Wire Business Wire • 03-01-2023
By Business Wire Business Wire • 05-11-2023
By Business Wire • 11-09-2023
By Business Wire Business Wire • 12-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.